Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.
about
Hedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancerIntestinal detoxification limits the activation of hepatic pregnane X receptor by lithocholic acid.Peroxisome proliferator-activated receptor α activates human multidrug resistance transporter 3/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretionBile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression.Role of cholangiocytes in primary biliary cirrhosis.Cholestasis induces reversible accumulation of periplakin in mouse liver.Lineage tracing demonstrates no evidence of cholangiocyte epithelial-to-mesenchymal transition in murine models of hepatic fibrosisFibrosis in autoimmune and cholestatic liver diseaseScoparone potentiates transactivation of the bile salt export pump gene and this effect is enhanced by cytochrome P450 metabolism but abolished by a PKC inhibitor.Successful surgical management of an extrahepatic biliary cystadenocarcinomaFibrates and cholestasisProteomic Analysis of the Rat Canalicular Membrane Reveals Expression of a Complex System of P4-ATPases in LiverMolecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode.Role of interleukin-1 and its antagonism of hepatic stellate cell proliferation and liver fibrosis in the Abcb4(-/-) mouse model.Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease.Curcumin improves sclerosing cholangitis in Mdr2-/- mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation.FXR agonists enhance the sensitivity of biliary tract cancer cells to cisplatin via SHP dependent inhibition of Bcl-xL expression.Heparin-binding epidermal growth factor-like growth factor and hepatocyte growth factor inhibit cholestatic liver injury in mice through different mechanisms.Hepatic inflammation and progressive liver fibrosis in chronic liver disease.Genetic variations of bile salt transporters as predisposing factors for drug-induced cholestasis, intrahepatic cholestasis of pregnancy and therapeutic response of viral hepatitis.Hepatobiliary transporters in drug-induced cholestasis: a perspective on the current identifying tools.NCX 1000 Alone or in Combination with Vitamin E Reverses Experimental Nonalcoholic Steatohepatitis in the Rat Similarly to UDCA.Role of Multidrug Resistance Protein 3 in Antifungal-Induced Cholestasis.Impact of bile acids on the growth of human cholangiocarcinoma via FXR.Bile acids affect the growth of human cholangiocarcinoma via NF-kB pathway.Synthetic FXR agonist GW4064 is a modulator of multiple G protein-coupled receptorsImpaired bile acid handling and aggravated liver injury in mice expressing a hepatocyte-specific RXRα variant lacking the DNA-binding domain.Cutting edge issues in primary sclerosing cholangitis.Activation of the cholehepatic shunt as a potential therapy for primary sclerosing cholangitis.Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes.Primary biliary cholangitis: new treatments for an old disease.Characterization of a novel organic solute transporter homologue from Clonorchis sinensis.Thyroid hormone receptor β1 stimulates to increase biliary phosphatidylcholine excretion in miceCholestatic liver diseases: new targets, new therapies
P2860
Q27322930-E8439A02-BF23-44D5-8696-143440D85EB9Q33574639-264006EC-0EB6-4FBD-9EE3-3F62588FCB37Q33725965-985B3B92-2FB1-42A4-9E0E-D36BE08DED3CQ34083354-173487DD-B812-470D-A939-04497262CF27Q34276575-8D8D7A31-3D57-4AE0-9F01-01A4B149EDD3Q34815606-3C9104BF-B582-4F6D-9098-9B53020219A3Q34862962-D68B9F1D-2E70-4D6F-B41E-415C877E93C1Q35098677-655FAFE7-DB9C-4F5B-A5D8-53143661A7DAQ35564302-E082997C-FC4E-423B-AF5F-CDC023E4DEDEQ35765513-37038D81-F5F3-43CD-9C5F-30EEB60C3624Q35889448-91C7F5EF-5348-492E-ABDF-0A3CC1BE678CQ36062197-A8C89286-6B53-4E8E-B975-709E1AE812FEQ36197335-16E8CC52-71DC-4E61-BBFB-F0985DC5A904Q36693626-C2F966EB-C3BA-47FF-ABC3-EA96F2BCB25CQ36769334-5DB8F8D9-7F64-4106-B20D-ABCFBD16C3ECQ37130129-5FCEDFFC-0D43-4DA8-9E09-310458C82023Q37376356-7C75382C-05F4-4050-9580-BC98E00BCABDQ37426647-1A2C412D-2207-4C47-9457-5BB15BBFC0A1Q37629675-31C33A53-7A7A-44F6-AFEE-9F097DE8A38FQ37841614-48159B39-EB5C-4AFF-91D1-7F06D9133B43Q38192698-FF9DBDD8-5516-4036-BD83-BAD151F63F1DQ38733145-616351EA-2D25-4B13-A2B2-0BFF04474684Q38775583-3302ACCD-2435-4939-8171-A3A1FF7B0CECQ38937273-63D87810-720B-4AFA-93C8-70B873BC04F2Q39202139-3A78EE41-2894-42B2-861A-E8D11E09CB66Q42253372-4C71AB58-DAC9-4AC0-BCF6-A5159DB27B33Q42417111-00C67886-D8C9-413E-8B62-A5C42C6CFCC8Q44391213-4C3B3E5A-C387-4DE0-91D3-BE5272CCE6B5Q45993134-CFE51E6A-B0D6-4646-B819-21AC5274D7CBQ54040784-A37255EF-7CB5-4011-95FB-7C37D016FC03Q54390436-90F0B561-24F9-4486-9E35-964FF0E1EBC0Q54985457-74437F42-2ED8-400E-9CE0-3B32632CACBDQ57109925-C202D5CF-B648-499F-9081-C11C652C6296Q57111104-FA477605-1035-4B04-8D21-A5E491915D67
P2860
Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Lessons from the toxic bile co ...... of cholestatic liver diseases.
@ast
Lessons from the toxic bile co ...... of cholestatic liver diseases.
@en
Lessons from the toxic bile co ...... of cholestatic liver diseases.
@nl
type
label
Lessons from the toxic bile co ...... of cholestatic liver diseases.
@ast
Lessons from the toxic bile co ...... of cholestatic liver diseases.
@en
Lessons from the toxic bile co ...... of cholestatic liver diseases.
@nl
prefLabel
Lessons from the toxic bile co ...... of cholestatic liver diseases.
@ast
Lessons from the toxic bile co ...... of cholestatic liver diseases.
@en
Lessons from the toxic bile co ...... of cholestatic liver diseases.
@nl
P2860
P1476
Lessons from the toxic bile co ...... of cholestatic liver diseases.
@en
P2093
Emina Halilbasic
Michael Trauner
P2860
P2888
P304
P356
10.1007/S10354-008-0592-1
P577
2008-01-01T00:00:00Z
P5875
P6179
1029685581